Please ensure Javascript is enabled for purposes of website accessibility

Gilead Reports Positive Late-Stage Study Results for Remdesivir in Patients With Moderate COVID-19

By Keith Speights – Jun 1, 2020 at 10:41AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was good news -- but not great news -- for the biotech's antiviral drug.

On Monday, Gilead Sciences (GILD 4.80%) announced results from a phase 3 clinical trial evaluating remdesivir in treating hospitalized patients with moderate cases of COVID-19. The company stated that patients receiving a 5-day course of treatment with remdesivir plus the standard of care were 65% more likely to experience clinical improvement at day 11 than patients receiving the standard of care alone. 

What it means

The results for remdesivir are encouraging in that they show that early intervention with remdesivir can help patients with moderate cases of COVID-19. Gilead previously announced positive results from another phase 3 study of the antiviral drug in patients with severe cases of the novel coronavirus. The National Institute of Allergy and Infectious Diseases also conducted a late-stage study that showed early treatment with remdesivir led to improved clinical outcomes.

Magnifying glass over blocks spelling remdesivir

Image source: Getty Images.

In addition, the safety profile for remdesivir appeared to be consistent with these previous studies. Gilead reported that the drug was generally well-tolerated; the most common adverse events included nausea, diarrhea, and headache.

However, the results from the latest study weren't quite as good as had been hoped for. The 10-day treatment course of remdesivir showed some clinical improvement compared to standard of care, but didn't reach statistical significance.

What's next

Gilead stated that it plans to submit the full data from its phase 3 study for publication in a peer-reviewed scientific journal within the next few weeks. The company is also conducting an expansion phase of the study that will enroll up to 1,000 additional patients. The results from that next phase are expected within the next few months.

Keith Speights owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$65.31 (4.80%) $2.99

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
331%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.